摘要
目的:通过检测毒性弥漫性甲状腺肿,即G raves’病(GD)患者的TPOAb与TRAb,探讨二者的应用与临床价值。方法:对于GD病人27例、GD病人治愈组10例、正常对照35例,采用R IA检测TPOAb与RRA检测TRAb并进行组间显著性比较。结果:GD病人的TPOAb与TRAb的测值和阳性率都显著高于GD病人治愈组和正常对照组,与GD病人治愈组和正常对照组相比较均有十分明显的差异,P值均<0.01。结论:GD病人TPOAb与TRAb的变化与病情的进展有较为密切的关系,对于GD的诊断与疗效观察具有较重要的参考价值。
Objective To investigate the significance of changes of serum TPOAb and TRAb levels in patients with Graves＇ disease （GD）. Methods Serum TPOAb （with RIA） and TRAb （with RRA） levels were determined in 27 patients with Graves＇ disease, before treatment 10 patients with Graves＇ disease clinically cured and 35 controls. Results The serum levels and positive rates of TPOAb and TRAb in patients with Graves＇ disease before treatment were significantly higher than those in the patients with Graves＇ disease clinically cured and controls （P 〈 0.01）. Conclusion TPOAb and TRAb were involved in the pathogenesis of Graves＇ disease and could be used as diagnostic and treatment indicators.
出处
《放射免疫学杂志》
CAS
2006年第5期361-362,共2页
Journal of Radioimmanology
